Video

Biosimilar Interchangeability

Interchangeability designations for biosimilars would make therapy substitutions easier for pharmacists, noted Steven Lucio of Novation, but the FDA has said they will not grant an interchangeability status to a biosimilar upon initial approval.

Interchangeability designations for biosimilars would make therapy substitutions easier for pharmacists, noted Steven Lucio of Novation, but the FDA has said they will not grant an interchangeability status to a biosimilar upon initial approval.

This video was shot at the 2013 Academy of Managed Care Pharmacy in San Antonio, Texas.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Image credit: viperagp | stock.adobe.com
Image credit: kitsawet | stock.adobe.com
Inflammation concept, inflammated human tissues 3d rendering - Image credit: picture-waterfall | stock.adobe.com
Related Content
Humira (adalimumab), reference product to Hadlima, Hyrimoz -- Image credit: Boris | stock.adobe.com
July 4th 2025

Real-World Data Shows Similar Clinical Outcomes in Patients Receiving Biosimilars Following Switch From Reference Product

Gillian McGovern, Associate Editor
Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder
March 31st 2025

Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder

Luke Halpern, Assistant Editor
The Future of Top-Selling Biologics: Biosimilars on the Rise
July 2nd 2025

The Future of Top-Selling Biologics: Biosimilars on the Rise

Matthew Haddad, PharmD Candidate 2026
Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education
February 28th 2025

Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education

Luke Halpern, Assistant Editor Jill Simonian, PharmD Codi Peterson, PharmD, MS
Cardiomyopathy (ATTR-CM) -- Image credit: Dzmitry | stock.adobe.com
July 1st 2025

Pharmacists Have a Crucial Role Helping Patients With ATTR-CM Navigate Treatment With Tafamidis

Gillian McGovern, Associate Editor Jennifer Goldman, PharmD, CDES, BC-ADM, FCCP
FDA Approved Food and Drug Administration concept. Person with FDA icon on virtual screen for Health product standards control system.
June 30th 2025

FDA Approves Emapalumab-Lzsg as First-Ever Treatment for Macrophage Activation Syndrome in Still Disease

Luke Halpern, Assistant Editor